Merck’s Human Vaccines Business in 4Q17
Human vaccines franchise
Merck & Co.’s (MRK) human vaccines franchise includes the Gardasil franchise, ProQuad/Varivax, RotaTeq, Pneumovax 23, and Zostavax. The total revenues from the human vaccines portfolio were ~$1.58 billion in 4Q17, a marginal increase compared to ~$1.57 million in 4Q16. The chart below shows revenues of the Gardasil franchise since 1Q16.
Interested in MRK? Don't miss the next report.
Receive e-mail alerts for new research on MRK
The Gardasil franchise includes vaccines used to prevent certain strains of sexually transmitted human papillomavirus (or HPV) infections. HPV can cause cervical, vulvar, anal, penile, and vaginal cancer, as well as genital warts. The Gardasil franchise reported total sales of $633.0 million in 4Q17, representing 17.0% growth compared to $542.0 million in 4Q16.
Gardasil sales also include $115.0 million due to partial replenishment of doses of Gardasil 9 vaccines borrowed from the US Centers for Disease Control and Prevention’s Pediatric Vaccine stockpile in 3Q17. GlaxoSmithKline’s (GSK) Cervarix is also approved for the prevention of HPV infection.
Other human vaccines
Other human vaccines include ProQuad/Varivax, Pneumovax 23, RotaTeq, and Zostavax. The revenues for ProQuad/Varivax fell 1.0% at constant exchange rates to $403.0 million in 4Q17 compared to $405.0 million in 4Q16.
Pneumovax 23 is a pneumococcal vaccine used for protection from pneumococcus infections. Pneumovax 23 reported sales of $263.0 million in 4Q17, representing 11.0% growth compared to $238.0 million in 4Q16.
Rotateq, a Rotavirus vaccine, reported revenues of $160.0 million in 4Q17 compared to revenues of $162.0 million in 4Q16.
Zostavax helps prevent herpes zoster infection in adults aged over 50 years. Zostavax reported revenues of $121.0 million in 4Q17 compared to $221.0 million in 4Q16. Other vaccines for herpes zoster infection include GlaxoSmithKline’s (GSK) Shingrix.